STAT+: Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is comparatively ambitious. We plan to dispose of sundry items at a neighborhood yard sale, hang with one of our short people, and promenade extensively with the official mascot. And what about you? This is a grand time to enjoy the great outdoors. You could catch up on your reading or plan a summer getaway. Of course, there is always the default strategy: simply take several naps. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
Two U.S. senators are workshopping a new idea to slash insulin costs: dangling incentives to convince drugmakers to lower prices of their own free will, STAT tells us. The idea is largely based on a common complaint from drug companies their sticker prices are sky-high because they have to pay insurers to get more favorable coverage for their medicines. The policy would ban those payments to insurers and cap patient monthly out-of-pocket costs for insulin, but only if drugmakers agree to reduce their prices to 2006 levels. Back then, a vial of insulin lawmakers cited cost about $68 without insurance; in 2019, it ran as much as $300.
Continue to STAT+ to read the full story…
